Invivyd (IVVD) Return on Capital Employed (2021 - 2025)
Invivyd (IVVD) reported Return on Capital Employed of 31.96% for Q4 2025, up 17926.0% on a YoY basis from N/an in Q4 2024, and up 64.23% quarter-over-quarter from 89.35% in Q3 2025.
Invivyd (IVVD) Return on Capital Employed (2021 - 2025) Analysis & Trends
Invivyd has reported Return on Capital Employed for 5 years, with the latest figure at 31.96% in Q4 2025.
- For the quarter ending Q4 2025, Return on Capital Employed rose 17926.0% year-over-year to 31.96%; the trailing twelve-month figure through Dec 2025 stood at 31.96% (up 17926.0% YoY), and the FY2025 full-year result was 32.87%, up 11783.0% from the prior year.
- Return on Capital Employed for Q4 2025 stood at 31.96%, up from 89.35% in the prior quarter.
- The five-year high for Return on Capital Employed was 31.96% in Q4 2025, with the low at 257.32% in Q3 2024.
- Historically, Return on Capital Employed has averaged 109.97% across 5 years, with a median of 69.25% in 2022.
- Annual changes were most pronounced in 2024 — Return on Capital Employed plunged 18868 bps — and 2025, when it soared 17926 bps.
- Invivyd's Return on Capital Employed stood at 38.39% in 2021, then slumped by 71 bps to 65.46% in 2022, then tumbled by 61 bps to 105.45% in 2023, then plunged by 100 bps to 211.21% in 2024, then surged by 85 bps to 31.96% in 2025.
- The last three Return on Capital Employed figures came in at 31.96% (Q4 2025), 89.35% (Q3 2025), and 218.35% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Invivyd | 168.41 Mn | -58.28 Mn | - | -31.96% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -31.96% |
| Sep 30, 2025 | -89.35% |
| Jun 30, 2025 | -218.35% |
| Mar 31, 2025 | -220.35% |
| Dec 31, 2024 | -211.21% |
| Sep 30, 2024 | -257.32% |
| Jun 30, 2024 | -134.72% |
| Mar 31, 2024 | -118.17% |
| Dec 31, 2023 | -105.45% |
| Sep 30, 2023 | -68.64% |
| Jun 30, 2023 | -62.73% |
| Mar 31, 2023 | -54.05% |
| Dec 31, 2022 | -65.46% |
| Sep 30, 2022 | -69.25% |
| Jun 30, 2022 | -65.40% |
| Mar 31, 2022 | -58.65% |
| Dec 31, 2021 | -38.39% |